NovoCure Limited (NVCR)
USD 18.15
(1.11%)
USD 18.15
(1.11%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -207.04 Million USD | -123.75% |
| 2022 | -92.53 Million USD | -58.58% |
| 2021 | -58.35 Million USD | -394.58% |
| 2020 | 19.8 Million USD | 373.97% |
| 2019 | -7.23 Million USD | 88.62% |
| 2018 | -63.55 Million USD | -3.08% |
| 2017 | -61.66 Million USD | 53.23% |
| 2016 | -131.84 Million USD | -18.16% |
| 2015 | -111.58 Million USD | -38.3% |
| 2014 | -80.68 Million USD | -4.28% |
| 2013 | -77.37 Million USD | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q1 | -38.76 Million USD | 17.67% |
| 2024 Q2 | -33.37 Million USD | 13.89% |
| 2024 Q3 | -30.57 Million USD | 8.4% |
| 2023 FY | -207.04 Million USD | -123.75% |
| 2023 Q2 | -57.41 Million USD | -8.21% |
| 2023 Q3 | -49.48 Million USD | 13.82% |
| 2023 Q4 | -47.07 Million USD | 4.86% |
| 2023 Q1 | -53.06 Million USD | -42.24% |
| 2022 Q1 | -4.64 Million USD | 82.44% |
| 2022 Q3 | -26.57 Million USD | -10.7% |
| 2022 Q4 | -37.3 Million USD | -40.36% |
| 2022 FY | -92.53 Million USD | -58.58% |
| 2022 Q2 | -24 Million USD | -416.63% |
| 2021 Q4 | -26.45 Million USD | -101.6% |
| 2021 FY | -58.35 Million USD | -394.58% |
| 2021 Q1 | -4.12 Million USD | -183.95% |
| 2021 Q2 | -14.64 Million USD | -254.68% |
| 2021 Q3 | -13.12 Million USD | 10.36% |
| 2020 FY | 19.8 Million USD | 373.97% |
| 2020 Q4 | 4.91 Million USD | -47.04% |
| 2020 Q3 | 9.28 Million USD | 460.97% |
| 2020 Q2 | 1.65 Million USD | -58.12% |
| 2020 Q1 | 3.95 Million USD | -7.23% |
| 2019 Q4 | 4.26 Million USD | 120.73% |
| 2019 Q1 | -12.15 Million USD | 22.27% |
| 2019 Q2 | -1.27 Million USD | 89.55% |
| 2019 FY | -7.23 Million USD | 88.62% |
| 2019 Q3 | 1.93 Million USD | 251.97% |
| 2018 Q3 | -11.69 Million USD | 24.6% |
| 2018 Q1 | -20.72 Million USD | -89.35% |
| 2018 FY | -63.55 Million USD | -3.08% |
| 2018 Q4 | -15.63 Million USD | -33.67% |
| 2018 Q2 | -15.51 Million USD | 25.16% |
| 2017 Q1 | -18.04 Million USD | 18.6% |
| 2017 Q2 | -21.17 Million USD | -17.34% |
| 2017 Q4 | -10.94 Million USD | 4.81% |
| 2017 Q3 | -11.49 Million USD | 45.7% |
| 2017 FY | -61.66 Million USD | 53.23% |
| 2016 Q1 | -35.43 Million USD | -7.62% |
| 2016 Q3 | -33.62 Million USD | 17.2% |
| 2016 Q4 | -22.16 Million USD | 34.08% |
| 2016 Q2 | -40.61 Million USD | -14.6% |
| 2016 FY | -131.84 Million USD | -18.16% |
| 2015 Q1 | -23.27 Million USD | -1.56% |
| 2015 FY | -111.58 Million USD | -38.3% |
| 2015 Q3 | -26.02 Million USD | 11.36% |
| 2015 Q2 | -29.35 Million USD | -26.14% |
| 2015 Q4 | -32.92 Million USD | -26.53% |
| 2014 FY | -80.68 Million USD | -4.28% |
| 2014 Q1 | -18.11 Million USD | 0.0% |
| 2014 Q2 | -21.32 Million USD | -17.71% |
| 2014 Q3 | -18.32 Million USD | 14.1% |
| 2014 Q4 | -22.91 Million USD | -25.09% |
| 2013 FY | -77.37 Million USD | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Akoya Biosciences, Inc. | -63.32 Million USD | -226.963% |
| AngioDynamics, Inc. | -184.34 Million USD | -12.31% |
| AtriCure, Inc. | -30.43 Million USD | -580.212% |
| Avinger, Inc. | -18.32 Million USD | -1030.147% |
| Azenta, Inc. | -14.25 Million USD | -1352.22% |
| BioLife Solutions, Inc. | -66.42 Million USD | -211.685% |
| The Cooper Companies, Inc. | 294.2 Million USD | 170.375% |
| Daxor Corporation | 280.64 Thousand USD | 73875.299% |
| Ekso Bionics Holdings, Inc. | -15.19 Million USD | -1262.304% |
| Femasys Inc. | -14.24 Million USD | -1353.227% |
| GlucoTrack, Inc. | -7.09 Million USD | -2817.331% |
| Harvard Bioscience, Inc. | -3.41 Million USD | -5962.753% |
| Hologic, Inc. | 789.5 Million USD | 126.225% |
| ICU Medical, Inc. | -29.65 Million USD | -598.172% |
| Intuitive Surgical, Inc. | 1.79 Billion USD | 111.515% |
| KORU Medical Systems, Inc. | -13.74 Million USD | -1406.747% |
| LeMaitre Vascular, Inc. | 30.1 Million USD | 787.736% |
| Innovative Eyewear, Inc. | -6.66 Million USD | -3007.154% |
| Innovative Eyewear, Inc. | -6.66 Million USD | -3007.154% |
| Masimo Corporation | 81.5 Million USD | 354.04% |
| Microbot Medical Inc. | -10.74 Million USD | -1827.775% |
| Meihua International Medical Technologies Co., Ltd. | 11.62 Million USD | 1880.951% |
| Merit Medical Systems, Inc. | 94.41 Million USD | 319.3% |
| Nephros, Inc. | -1.57 Million USD | -13045.587% |
| NEXGEL, Inc. | -3.15 Million USD | -6458.22% |
| NEXGEL, Inc. | -3.15 Million USD | -6458.22% |
| Singular Genomics Systems, Inc. | -94.82 Million USD | -118.354% |
| OraSure Technologies, Inc. | 53.65 Million USD | 485.878% |
| Pro-Dex, Inc. | 2.12 Million USD | 9834.039% |
| Pulse Biosciences, Inc. | -42.21 Million USD | -390.507% |
| Predictive Oncology Inc. | -13.98 Million USD | -1380.574% |
| Precision Optics Corporation, Inc. | -2.95 Million USD | -6915.132% |
| QuidelOrtho Corporation | -10.1 Million USD | -1949.931% |
| Repligen Corporation | 41.57 Million USD | 597.975% |
| Sanara MedTech Inc. | -4.3 Million USD | -4711.376% |
| STAAR Surgical Company | 21.34 Million USD | 1069.893% |
| Sharps Technology, Inc. | -9.84 Million USD | -2003.745% |
| Utah Medical Products, Inc. | 16.63 Million USD | 1344.623% |
| DENTSPLY SIRONA Inc. | -132 Million USD | -56.851% |
| Jin Medical International Ltd. | 2.87 Million USD | 7293.414% |